0.8085
1.19%
0.0095
Handel nachbörslich:
.82
0.0115
+1.42%
Schlusskurs vom Vortag:
$0.799
Offen:
$0.771
24-Stunden-Volumen:
88,639
Relative Volume:
0.32
Marktkapitalisierung:
$93.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.86M
KGV:
-0.4517
EPS:
-1.79
Netto-Cashflow:
$-125.29M
1W Leistung:
+3.80%
1M Leistung:
+3.75%
6M Leistung:
+7.10%
1J Leistung:
-62.40%
Allovir Inc Stock (ALVR) Company Profile
Firmenname
Allovir Inc
Sektor
Branche
Telefon
(617) 433-2605
Adresse
1100 WINTER STREET, WALTHAM
Allovir Inc Stock (ALVR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
2020-08-24 | Eingeleitet | JP Morgan | Overweight |
2020-08-24 | Eingeleitet | Morgan Stanley | Overweight |
2020-08-24 | Eingeleitet | SVB Leerink | Outperform |
Allovir Inc Aktie (ALVR) Neueste Nachrichten
AlloVir (NASDAQ:ALVR) Shares Up 1% - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC - Defense World
AlloVir (NASDAQ:ALVR) Trading 1% Higher - MarketBeat
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - ForexTV.com
Upward Trajectory: AlloVir Inc (ALVR) Posts a Gaine, Closing at 0.78 - The Dwinnex
Investigation announced for Investors who lost money with - openPR
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Head to Head Analysis: Vaxcyte (NASDAQ:PCVX) & AlloVir (NASDAQ:ALVR) - Defense World
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com India
Allovir CEO Diana Brainard sells shares worth nearly $4,000 By Investing.com - Investing.com Australia
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com
Allovir executive sells shares to cover tax obligations - Investing.com
Allovir CEO Diana Brainard sells shares worth over $2,300 - Investing.com
Vanguard Group Inc. Lowers Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Price T Rowe Associates Inc. MD Buys 54,900 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
ALVR (AlloVir) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
AlloVir (NASDAQ:ALVR) Posts Earnings Results, Beats Expectations By $0.05 EPS - Defense World
B of A Securities Initiates Coverage of AlloVir (ALVR) with Buy Recommendation - MSN
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
Analyzing Immunovant (NASDAQ:IMVT) & AlloVir (NASDAQ:ALVR) - Defense World
AlloVir Inc (ALVR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Yahoo Finance
AlloVir, Inc. (NASDAQ:ALVR) Sees Large Decline in Short Interest - MarketBeat
Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 6.3% - American Banking and Market News
Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 6.3% - Defense World
Acadian Asset Management LLC Has $1.20 Million Stake in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Acadian Asset Management LLC Buys 1,387,666 Shares of AlloVir, Inc. (NASDAQ:ALVR) - MarketBeat
Allovir's general counsel sells over $1,000 in stock - Investing.com
Allovir executive sells over $2500 in company stock - Investing.com
Allovir executive sells over $2500 in company stock By Investing.com - Investing.com Canada
Parainfluenza Virus Infection Drugs Market Size 2032 | - openPR
AlloVir, Inc. Expected to Earn Q2 2024 Earnings of ($0.07) Per Share (NASDAQ:ALVR) - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Forecasted to Post Q2 2024 Earnings of ($0.07) Per Share - MarketBeat
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Simply Wall St
Investing in AlloVir Inc (ALVR) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
AlloVir (NASDAQ:ALVR) Trading Up 3.3% - MarketBeat
AlloVir (NASDAQ:ALVR) Trading Up 3.3% - Defense World
Taking a Closer Look At AlloVir Inc (ALVR) Following Its Recent Trade - Knox Daily
AlloVir Investor Deadline Approaching - Newsfile
Allovir CEO Diana Brainard sells shares worth over $1,000 By Investing.com - Investing.com Canada
Jacobs solutions executive chair sells $979k in stock By Investing.com - Investing.com
Allovir CEO Diana Brainard sells shares worth over $1,000 By Investing.com - Investing.com India
Eliem Therapeutics EVP sells $338,000 in stock By Investing.com - Investing.com India
Taking a Closer Look At AlloVir Inc (ALVR) Following Its Recent Trade – Knox Daily - Knox Daily
Nothing is Better Than AlloVir Inc (ALVR) stock at the moment – Sete News - SETE News
SEC Form 144 filed by AlloVir Inc. - Quantisnow
AlloVir ends lease early, pays $7 million termination fee - Investing.com
AlloVir Finalizes $7 Million Lease Termination Deal - TipRanks
AlloVir ends lease early, pays $7 million termination fee By Investing.com - Investing.com UK
Is AlloVir Inc (ALVR) worth investing in despite its overvalued state? – US Post News - US Post News
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% - Yahoo New Zealand News
Finanzdaten der Allovir Inc-Aktie (ALVR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):